Advertisement
ABT vs BAX
Which Stock Would AI Choose? Abbott Laboratories (ABT) vs. Baxter International (BAX) Stock Comparison
Key Takeaways
- Different business profiles: ABT is a diversified healthcare giant spanning medical devices, diagnostics, nutrition, and pharmaceuticals, while BAX is a focused hospital-products and medical-technology turnaround story.
- Relative performance has diverged: Abbott shares have declined sharply over the past year, while Baxter has rallied strongly in recent months amid an improving outlook.
- Growth versus recovery: Abbott is scaling through product launches and the Exact Sciences acquisition; Baxter is rebuilding growth after divesting its Kidney Care business.
- Risk profiles differ: Abbott faces nutrition litigation and integration costs, while Baxter contends with margin compression and an unresolved infusion-pump shipment hold.
- AI-style positioning: A systematic, trend-aware framework would weigh Abbott's steadier cash flows against Baxter's stronger near-term momentum.
Introduction
Investors comparing ABT and BAX are effectively weighing two very different ways to gain exposure to the healthcare sector. Abbott Laboratories is a diversified, large-cap operator with a broad product portfolio and a premium valuation, while Baxter International is a mid-cap medical-products company navigating a post-divestiture recovery. This stock comparison is especially relevant for traders and investors who want to understand how business-model breadth, recent momentum, and execution risk shape relative performance and market positioning across two names that serve overlapping hospital and device end-markets.
ABT Overview and Recent Performance
Abbott Laboratories operates four major segments: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals. In recent weeks, the company has maintained a steady stream of regulatory and product news, including approvals for its TactiFlex Duo ablation catheter and Libre Duo glucose-ketone sensing system, as well as the launch of new nutrition products. These launches have supported Medical Devices growth, with Electrophysiology and Diabetes Care posting solid gains.
Sentiment, however, remains mixed. Abbott completed its roughly $20.6 billion acquisition of Exact Sciences earlier in 2026, strengthening its Cancer Diagnostics franchise, yet the stock has fallen significantly over the past year and year to date, reflecting softer comparable sales growth in some quarters, ongoing Nutrition weakness, and a $385 million settlement tied to its earlier infant formula recall. The company raised its full-year adjusted earnings per share (EPS) guidance after a second-quarter beat, but valuation remains a point of debate, with shares trading on a higher multiple relative to some medical-equipment peers.
BAX Overview and Recent Performance
Baxter International is a medical-products company focused on hospital care, organized around Medical Products & Therapies and Healthcare Systems & Technologies. The company has been reshaping its portfolio, most notably divesting its Kidney Care business to Carlyle in early 2025 to reduce leverage and sharpen its focus. In recent months, Baxter has shown signs of an early-stage turnaround, raising its full-year 2026 sales and adjusted EPS outlook after second-quarter results exceeded expectations.
That improving backdrop has driven a strong rebound in the shares, which have rallied sharply over the trailing 90-day period. Advanced Surgery has been a bright spot, growing in the low double digits, while recurring hospital consumables provide a steady revenue base. Still, the recovery is incomplete: adjusted gross and operating margins have compressed under higher-cost inventory and tariffs, and an ongoing shipment-and-installation hold on the Novum IQ large-volume infusion pump continues to weigh on Infusion Systems sales. Baxter has also cut its quarterly dividend, underscoring the balance-sheet pressures that remain part of the story.
Trending AI Robots
Tickeron operates a marketplace of hundreds of AI trading bots, each built on proprietary Financial Learning Models (FLMs) that scan markets, detect patterns, and generate trade signals across thousands of tickers. Because these bots span different styles, strategies, timeframes, and performance statistics, not every robot suits every market environment. The Trending AI Robots section curates only the bots currently considered most suitable for prevailing market conditions, allowing traders to filter by strategy, timeframe, and the specific tickers each robot trades. For those tracking healthcare names like ABT and BAX, exploring this section can surface signal-based, virtual, and brokerage-connected agents with published trade histories and distinct risk profiles.
Head-to-Head Comparison
The core contrast between these two stocks is one of scale and diversification versus focused recovery. Abbott's breadth—spanning devices, diagnostics, nutrition, and branded generics—provides multiple growth levers and a larger, steadier earnings base, but it also exposes the company to segment-specific headwinds and a richer valuation. Baxter, by comparison, offers a leaner, hospital-centric model with recurring consumables revenue, yet its turnaround hinges on margin recovery and resolving the infusion-pump hold.
Growth drivers differ accordingly. Abbott is leveraging new device approvals and the Exact Sciences integration, while Baxter is rebuilding through Advanced Surgery momentum and cost discipline. On momentum, Baxter has outperformed sharply in recent months, while Abbott's trend has been weaker despite improving fundamentals. Risk factors also diverge: Abbott's are tied to nutrition litigation and acquisition integration, while Baxter's center on margins, tariffs, and regulatory execution. Finally, market sentiment reflects this split—analysts have turned more constructive on Abbott's valuation and pipeline, even as Baxter's rally has reset expectations higher for continued execution.
Tickeron AI Verdict
Based on observable trend consistency, stability, and catalyst positioning, a systematic AI framework would likely favor ABT for stability-oriented positioning, given its diversified cash flows, broad product momentum, and multiple near-term catalysts, despite weaker recent price action. Conversely, BAX presents a stronger short-term momentum profile but carries more execution uncertainty around margins and the infusion-pump hold. In probabilistic terms, the AI would tend to weight Abbott's steadier fundamentals and clearer catalyst path more favorably for medium-term positioning, while treating Baxter's rebound as a higher-beta, momentum-driven opportunity that remains dependent on continued operational follow-through.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABT is a Hold and BAX is a Hold.
ABT in +2.49% Uptrend, rising for three consecutive days on October 16, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ABT advanced for three days, in 172 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ABT's RSI Indicator exited the oversold zone, 18 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 49%.
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on ABT as a result. In 46 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 53%.
The Moving Average Convergence Divergence (MACD) for ABT just turned positive on October 09, 2026. Looking at past instances where ABT's MACD turned positive, the stock continued to rise in 25 of 54 cases over the following month. The odds of a continued upward trend are 46%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 28 of 54 cases where ABT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 52%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
ABT broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ABT entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 5 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. ABT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 68 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.403) is normal, around the industry mean (2.874). P/E Ratio (32.423) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (1.853) is also within normal values, averaging (11.052). Dividend Yield (0.025) settles around the average of (0.009) among similar stocks. P/S Ratio (3.836) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
BAX in upward trend: 10-day moving average moved above 50-day moving average on October 22, 2026
The 10-day moving average for BAX crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 30, 2026. You may want to consider a long position or call options on BAX as a result. In 48 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 56%.
The Moving Average Convergence Divergence (MACD) for BAX just turned positive on September 30, 2026. Looking at past instances where BAX's MACD turned positive, the stock continued to rise in 21 of 45 cases over the following month. The odds of a continued upward trend are 47%.
BAX moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.65% 3-day Advance, the price is estimated to grow further. Considering data from situations where BAX advanced for three days, in 166 of 288 cases, the price rose further within the following month. The odds of a continued upward trend are 58%.
The Aroon Indicator entered an Uptrend today. In 143 of 210 cases where BAX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 68%.
Bearish Trend Analysis
The 10-day RSI Indicator for BAX moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 33 similar instances where the indicator moved out of overbought territory. In 18 of the 33 cases, the stock moved lower in the following days. This puts the odds of a move lower at 55%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 33 of 55 cases where BAX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 60%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 68%.
BAX broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 16 (best 1 - 100 worst), indicating outstanding price growth. BAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.058) is normal, around the industry mean (4.961). P/E Ratio (-11.932) is within average values for comparable stocks, (37.232). BAX's Projected Growth (PEG Ratio) (36.677) is very high in comparison to the industry average of (4.143). Dividend Yield (0.002) settles around the average of (0.005) among similar stocks. P/S Ratio (1.057) is also within normal values, averaging (56.876).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
ABT | BAX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 14 | 10 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 70 Overvalued | 96 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 68 | 94 | |
PRICE GROWTH RATING 1..100 | 55 | 16 | |
P/E GROWTH RATING 1..100 | 5 | 56 | |
SEASONALITY SCORE 1..100 | 65 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ABT's Valuation (70) in the Medical Specialties industry is in the same range as BAX (96). This means that ABT’s stock grew similarly to BAX’s over the last 12 months.
ABT's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as BAX (100). This means that ABT’s stock grew similarly to BAX’s over the last 12 months.
ABT's SMR Rating (68) in the Medical Specialties industry is in the same range as BAX (94). This means that ABT’s stock grew similarly to BAX’s over the last 12 months.
BAX's Price Growth Rating (16) in the Medical Specialties industry is somewhat better than the same rating for ABT (55). This means that BAX’s stock grew somewhat faster than ABT’s over the last 12 months.
ABT's P/E Growth Rating (5) in the Medical Specialties industry is somewhat better than the same rating for BAX (56). This means that ABT’s stock grew somewhat faster than BAX’s over the last 12 months.
| ABT | BAX | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 49% | 1 day ago 55% |
| Stochastic ODDS (%) | 1 day ago 52% | 1 day ago 60% |
| Momentum ODDS (%) | 1 day ago 53% | 1 day ago 56% |
| MACD ODDS (%) | 1 day ago 46% | 1 day ago 47% |
| TrendWeek ODDS (%) | 1 day ago 54% | 1 day ago 68% |
| TrendMonth ODDS (%) | 1 day ago 56% | 1 day ago 64% |
| Advances ODDS (%) | 7 days ago 56% | 1 day ago 58% |
| Declines ODDS (%) | 2 days ago 56% | 3 days ago 68% |
| BollingerBands ODDS (%) | 1 day ago 55% | 1 day ago 70% |
| Aroon ODDS (%) | 1 day ago 50% | 1 day ago 68% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABT’s FA Score shows that 1 FA rating(s) are green while BAX’s FA Score has 1 green FA rating(s).
- ABT’s FA Score: 1 green, 4 red.
- BAX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABT’s TA Score shows that 4 TA indicator(s) are bullish while BAX’s TA Score has 4 bullish TA indicator(s).
- ABT’s TA Score: 4 bullish, 4 bearish.
- BAX’s TA Score: 4 bullish, 5 bearish.
Price Growth
ABT (@Medical/Nursing Services) experienced а -2.07% price change this week, while BAX (@Pharmaceuticals: Other) price change was -0.40% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.50%. For the same industry, the average monthly price growth was -10.64%, and the average quarterly price growth was -10.25%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.74%. For the same industry, the average monthly price growth was -3.62%, and the average quarterly price growth was +9.09%.
Reported Earning Dates
ABT is expected to report earnings on Jan 27, 2027.
BAX is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Medical/Nursing Services (-1.50% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (+0.74% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
BAX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BAX has been loosely correlated with LUNG. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if BAX jumps, then LUNG could also see price increases.
| Ticker / NAME | Correlation To BAX | 1D Price Change % | ||
|---|---|---|---|---|
| BAX | 100% | +3.85% | ||
| LUNG - BAX | 53% Loosely correlated | +2.73% | ||
| ICUI - BAX | 52% Loosely correlated | +4.66% | ||
| STE - BAX | 51% Loosely correlated | +4.85% | ||
| SYK - BAX | 51% Loosely correlated | +3.19% | ||
| BDX - BAX | 49% Loosely correlated | +3.13% | ||
More | ||||